0000939767-23-000124.txt : 20231214
0000939767-23-000124.hdr.sgml : 20231214
20231214195605
ACCESSION NUMBER: 0000939767-23-000124
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231212
FILED AS OF DATE: 20231214
DATE AS OF CHANGE: 20231214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haley Patrick J.
CENTRAL INDEX KEY: 0001692954
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 231488558
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
4
1
wk-form4_1702601755.xml
FORM 4
X0508
4
2023-12-12
0
0000939767
EXELIXIS, INC.
EXEL
0001692954
Haley Patrick J.
C/O EXELIXIS, INC.
1851 HARBOR BAY PARKWAY
ALAMEDA
CA
94502
0
1
0
0
EVP, Commercial
1
Common Stock
2023-12-12
4
S
0
14149
22.50
D
307687
D
Common Stock
2023-12-14
4
M
0
50000
16.29
A
357687
D
Common Stock
2023-12-14
4
S
0
50000
23.35
D
307687
D
Common Stock
23539
I
By spouse
Common Stock
10648
I
By 401(k)
Option (right to buy)
16.29
2023-12-14
4
M
0
50000
0
D
2017-12-19
2023-12-18
Common Stock
50000
0
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2023.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.50 to $22.52. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
Includes 200,242 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.01 to $23.66. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of December 11, 2023.
The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 19, 2020.
/s/ Nina Ayer, Attorney in Fact
2023-12-14